3974-16-1

Usage

Uses

Used in Pharmaceutical Industry:
Pyrimidine, 4,6-dichloro-5-phenyl-, is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure and biological activities make it a promising candidate for the treatment of various diseases, including infections caused by fungi and viruses. Pyrimidine, 4,6-dichloro-5-phenyl-'s ability to modulate specific biological pathways and target pathogenic organisms contributes to its potential as a therapeutic agent.
Used in Agrochemical Industry:
In the agrochemical industry, Pyrimidine, 4,6-dichloro-5-phenyl-, is used as an active ingredient in fungicides and other crop protection products. Its antifungal properties help control fungal infections in crops, thereby improving crop yield and quality. Pyrimidine, 4,6-dichloro-5-phenyl-'s effectiveness against a broad spectrum of fungal pathogens makes it a valuable tool in agricultural practices.
Used in Materials Science:
Pyrimidine, 4,6-dichloro-5-phenyl-, is used as a building block in the synthesis of novel materials with specific properties. Its unique chemical structure allows for the creation of new organic compounds with potential applications in various fields, such as electronics, optoelectronics, and nanotechnology. Pyrimidine, 4,6-dichloro-5-phenyl-'s versatility in chemical reactions and its ability to form stable complexes with other molecules contribute to its utility in materials science.
Used in Chemical Synthesis:
Pyrimidine, 4,6-dichloro-5-phenyl-, is used as a key intermediate in the synthesis of a variety of organic compounds. Its reactivity and functional groups make it an ideal candidate for use in organic synthesis, where it can be further modified or combined with other molecules to create new compounds with specific properties and applications. This versatility in chemical synthesis broadens the scope of its potential uses across various industries.

Upstream product

• 18337-64-9 5-phenylpyrimidine-4,6-diol 
• 83-13-6 diethyl 2-phenylmalonate 
• 1312466-27-5 4,6-dichloro-2-(methylsulfonyl)-5-phenylpyrimidine 
• 103-82-2 phenylacetic acid 
• 101-41-7 benzeneacetic acid methyl ester 
• 64415-11-8 4,6-dichloro-2-methylthio-5-phenylpyrimidine 

Downstream Products

• 1312466-07-1 6-chloro-5-phenylpyrimidine-4-(9-O-quinidine) ether 
• 441797-36-0 C₁₇H₁₅ClN₄O₂S 
• 917395-99-4 4-chloro-6-(4-chlorophenyl)-5-phenylpyrimidine 
• 14630-97-8 dimethyl-(6-phenothiazin-10-yl-5-phenyl-pyrimidin-4-yl)-amine 
• 335063-11-1 4-chloro-6-[4-(5-methyl-1H-imidazol-4-yl)-piperidin-1-yl]-5-phenyl-pyrimidine 
• 14630-96-7 10-(6-chloro-5-phenyl-pyrimidin-4-yl)-10H-phenothiazine 

Relevant academic research and scientific papers

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

Asymmetric total syntheses of (-)-variabilin and (-)-glycinol

Total syntheses of (-)-variabilin and (-)-glycinol have been accomplished, using the catalytic, asymmetric "interrupted" Feist-Benary reaction (IFB) as the key transformation to introduce both stereogenic centers. A monoquinidine pyrimidinyl ether catalyst affords the IFB products in over 90% ee in both cases. Other key steps include an intramolecular Buchwald-Hartwig coupling and a nickel-catalyzed aryl tosylate reduction.

4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

A series of non-nucleoside adenosine kinase (AK) inhibitors is reported. These inhibitors originated from the modification of 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine (ABT-702). The identification of a linker that would approximate the spatial arrangement found between the pyrimidine ring and the aryl group at C(7) in ABT-702 was a key element in this modification. A search of potential linkers led to the discovery of an acetylene moiety as a suitable scaffold. It was hypothesized that the aryl acetylenes, ABT-702, and adenosine bound to the active site of AK (closed form) in a similar manner with respect to the orientation of the heterocyclic base. Although potent acetylene analogs were discovered based on this assumption, an X-ray crystal structure of 5-(4-dimethylaminophenyl)-6-(6-morpholin-4-ylpyridin-3-ylethynyl)pyrimidin-4-ylamine (16a) revealed a binding orientation contrary to adenosine. In addition, this compound bound tightly to a unique open conformation of AK. The structure-activity relationships and unique ligand orientation and protein conformation are discussed.

Triazolopyrimidine cannabinoid receptor 1 antagonists

The present application describes compounds according to both Formulas I and II, pharmaceutical compositions comprising at least one compound according to either Formula I or II and optionally one or more additional therapeutic agents, and methods of treatment using the compounds according to Formulas I and II both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formulas: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein R1, R2, R3, R4 and R5 are described herein.

Heterocyclic sodium/proton exchange inhibitors and method

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N. R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.